Immune Responses Elevation by Intranasal Administration of Chitosan Microparticles Adjuvanted Poly-Epitope against Streptococcus pneumoniae in BALB/c Mice Immune responses elevation against S. pneumoniae mice
Novelty in Biomedicine,
Vol. 10 No. 1 (2022),
31 January 2022
,
Page 17-26
https://doi.org/10.22037/nbm.v10i1.35527
Abstract
Background: Designing inhaled vaccine formulations against respiratory pathogens like Streptococcus
pneumoniae (S. pneumoniae) lead to more effective mucosal and local immunity in the upper respiratory tract.
Choosing chitosan (the chitin de-acetylated derivative) as a biocompatible, biodegradable, and non-toxic
biopolymer and a suitable mucosal adjuvant can help to stimulate both systemic cellular and humoral immunity,
as well as local protection, is valuable. The purpose of this study is the determination the ability of the designed
pneumococcal immunogenic polytope to evoke a bactericidal response when adjuvanted with chitosan
microparticles.
Materials and Methods: We chose virulence proteins from S. pneumoniae (Pneumolysin, Neuraminidase, ZinkMetalloproteinase, Hydrolase) and designed a new multi-epitope construct by linking their individual predicted
T and B cell epitopes. Intranasal immunization with PNEU protein and chitosan microparticle administered in
BALB/c mice.
Results: Our formulation showed enhanced systemic IgG-2a, IgA, and mucosal IgA antibody concentrations,
revealing significant humoral responses to the polytope. The polytope increases the number of IFN-γ-
producing cells in the re-stimulation of splenocytes in the culture medium and a rise in the concentrations of
IL-6, IL-17, and TNF-α along with the regulatory responses of IL-10 presented the capacity of the formulation
to provoke immune responses. The bactericidal test ultimately confirmed the high efficacy of the vaccine in
inhibiting the bacteria.
Conclusion: Immunological responses were significantly induced after intranasal administration of the S.
pneumoniae computational predicted polytope accompanied by chitosan microparticles as a potent mucosal
adjuvant. Bactericidal assay confirmed effective immune responses in S. pneumoniae inhibition.
- Poly-epitope, Streptococcus pneumonia, Chitosan micro-particles, Inhaled vaccine
How to Cite
References
Chiavolini D, Memmi G, Maggi T, Iannelli F, Pozzi G, Oggioni MR. The three extra-cellular zinc metalloproteinases of Streptococcus pneumoniae have a different impact on virulence in mice. BMC Microbiol. 2003;3:14.
Mellroth P, Daniels R, Eberhardt A, Rönnlund D, Blom H, Widengren J, et al. LytA, Major Autolysin of Streptococcus pneumoniae, Requires Access to Nascent Peptidoglycan. J Biol Chem. 2012;287:11018–29.
Daniels CC, Rogers PD, Shelton CM. A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens. J Pediatr Pharmacol Ther. 2016;21:27–35.
Wadhwani A, Khanna V. In Silico Identification of Novel Potential Vaccine Candidates in Streptococcus pneumoniae. J Informatics Data Min. 2016;1:1–8.
Haji Molla Hoseini M, Sadeghi S, Azizi M, Pouriran R. Immunomodulatory activities of chitin and chitosan microparticles. In: GOPI S, THOMAS S, PIUS A, editors. Handbook of chitin and chitosan: Chitin- and chitosan-based polymer materials for various applications. 3rd ed. Susan Dennis; 2020. p. 609–39.
Khan N, Jan AT. Towards Identifying Protective B-Cell Epitopes: The PspA Story. Front Microbiol. 2017;8:1–8.
Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: Transmission, colonization and invasion. Nat Rev Microbiol. 2018;16:355–67.
AlonsoDeVelasco E, Verheul AFM, Verhoef J, Snippe H. Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev. 1995;59:591–603.
Sharapova Y, Suplatov D, Švedas V. Neuraminidase A from Streptococcus pneumoniae has a modular organization of catalytic and lectin domains separated by a flexible linker. FEBS J. 2018;285:2428–45.
Harish Prashanth KV, Tharanathan RN. Chitin/chitosan: modifications and their unlimited application potential—an overview. Trends Food Sci Technol. 2007;18:117–31.
Verma A, Prasad KN, Singh AK, Nyati KK, Gupta RK, Paliwal VK. Evaluation of the MTT lymphocyte proliferation assay for the diagnosis of neurocysticercosis. J Microbiol Methods. 2010;81:175–8.
Swamydas M, Luo Y, Dorf ME, Lionakis MS. Isolation of Mouse Neutrophils. Curr Protoc Immunol. 2015;110:3.20.1-3.20.15.
Sadeghi S, Bandehpour M, HajiMollaHosseini M, Kazemi B. Designing and expression of an immunogenic poly-epitope protein from Streptococcus pneumoniae. TPPS.2021
Genschmer KR, Accavitti-Loper MA, Briles DE. A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA). Vaccine. 2013;32:39–47.
Cui L-M, Zhang K, Ma D-J, Liu S-P, Zhang X-W. Protein expression under sustained activation of signal transducer and activator of transcription-3 in diethylnitrosamine-induced rat liver carcinogenesis. Oncol Lett. 2014;8:608–14.
Ahire VJ, Sawant KK, Doshi JB, Ravetkar SD. Chitosan Microparticles as Oral Delivery System for Tetanus Toxoid. Drug Dev Ind Pharm [Internet]. 2007 Jan 25;33(10):1112–24. Available from: doi: 10.1080/03639040701377847
Van Der Lubben IM, Kersten G, Fretz MM, Beuvery C, Verhoef JC, Junginger HE. Chitosan microparticles for mucosal vaccination against diphtheria: Oral and nasal efficacy studies in mice. Vaccine. 2003;21(13–14):1400–8.
Jiang HL, Kang ML, Quan JS, Kang SG, Akaike T, Yoo HS, et al. The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. Biomaterials. 2008;29(12):1931–9.
Kang ML, Jiang HL, Kang SG, Guo DD, Lee DY, Cho CS, et al. Pluronic®F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin. Vaccine. 2007;25(23):4602–10.
Jaganathan KS, Vyas SP. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant Hepatitis B antigen administered intranasally. Vaccine. 2006;24(19):4201–11.
Baudner BC, Verhoef JC, Giuliani MM, Peppoloni S, Rappuoli R, Del Giudice G, et al. Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform. J Drug Target. 2005;13(8–9):489–98.
Dorosti H, Eslami M, Negahdaripour M, Ghoshoon MB, Gholami A, Heidari R, et al. Vaccinomics approach for developing multi-epitope peptide pneumococcal vaccine. J Biomol Struct Dyn. 2019;37:3524–35.
Fang L, Wolmarans B, Kang M, Jeong KC, Wright AC. Application of Chitosan Microparticles for Reduction of Vibrio Species in Seawater and Live Oysters (Crassostrea virginica). Appl Environ Microbiol. 2015;81:640–7.
Da Silva CA, Chalouni C, Williams A, Hartl D, Lee CG, Elias JA. Chitin Is a Size-Dependent Regulator of Macrophage TNF and IL-10 Production. J Immunol. 2009;182:3573–82.
Da Silva CA, Pochard P, Lee CG, Elias JA. Chitin Particles Are Multifaceted Immune Adjuvants. Am J Respir Crit Care Med. 2010;182:1482–91.
Da Silva CA, Hartl D, Liu W, Lee CG, Elias JA. TLR-2 and IL-17A in Chitin-Induced Macrophage Activation and Acute Inflammation. J Immunol. 2008;181:4279–86.
Ritchie ND, Ritchie R, Bayes HK, Mitchell TJ, Evans TJ. IL-17 can be protective or deleterious in murine pneumococcal pneumonia. PLOS Pathog. 2018;14:e1007099.
Moffitt KL, Gierahn TM, Lu YJ, Gouveia P, Alderson M, Flechtner JB, et al. TH17-based vaccine design for prevention of streptococcus pneumoniae colonization. Cell Host Microbe. 2011;9:158–65.
Kang ML, Cho CS, Yoo HS. Application of chitosan microspheres for nasal delivery of vaccines. Biotechnol Adv. 2009;27:857–65.
Li M, Wang Y, Sun Y, Cui H, Zhu SJ, Qiu H-J. Mucosal vaccines: Strategies and challenges. Immunol Lett. 2020;217:116–25.
- Abstract Viewed: 101 times
- pdf Downloaded: 142 times